What drove the ALVAL.PA stock spike today?

Intraday buying and heavy volume drove the move. Traders reacted to pipeline attention around TOTUM-63 and partner-related headlines. Volume was **1,258,606.00** vs avg **456,885.00**, suggesting momentum buying rather than a fundamentals shift.

What is Meyka AI's grade for ALVAL.PA stock?

Meyka AI rates ALVAL.PA **58.27/100**, Grade **C+**, Suggestion **HOLD**. The grade factors S&P and sector comparisons, growth metrics, financials and analyst signals. This is informational and not financial advice.

What price targets and forecast exist for ALVAL.PA stock?

Meyka AI's model lists a monthly reference **€0.88** and a quarterly reference **€1.02**. Compared with today’s **€1.18**, those imply downside of **-25.42%** and **-13.56%** respectively. Forecasts are model projections, not guarantees.

How risky is trading ALVAL.PA stock on EURONEXT?

Risk is high: Valbiotis is loss-making with negative EPS and binary clinical-event risk. Short-term liquidity looks adequate (**current ratio 3.04**), but trial or regulatory setbacks can cause sharp declines. Use strict risk controls.

EU Stocks

ALVAL.PA Valbiotis SA (EURONEXT) up 17.76% on 04 Feb 2026: market drivers to watch

ByHuzaifa Zahoor February 4, 2026February 4, 2026

ALVAL.PA stock rose sharply intraday to €1.18 on 04 Feb 2026, a 17.76% gain from yesterday’s close. The move comes on heavy volume of 1,258,606.00 shares vs an average of 456,885.00, signalling buyer interest in Valbiotis SA (EURONEXT). Traders are reacting to clinical trial milestones and renewed attention on the healthcare biotech sector in Europe. We review the intraday drivers, key financials, technical setup and the Meyka AI forecast to help traders frame short-term risk and opportunity for this top gainer.